摘要
目的 研究血管紧张素转换酶(ACE)基因I／D多态性和α-adducin基因G614T多态性与氢氯噻嗪降压疗效的关系。方法 829例原发性高血压患者同时服用氢氯噻嗪12.5mg，1次／d，6周后资料完整的754例患者按不同ACE基因型和α-adducin基因型分组，比较不同基因型组和组合基因型组血压下降值。结果 服用氢氯噻嗪6周后，DD基因型患者收缩压下降值大于II、ID型患者，差异有统计学意义(P＜0.05)。TT基因型患者收缩压下降值大于GG、GT型患者，差异有统计学意义(P＜0.01)；TT、GT基因型患者舒张压下降值大于GG基因型患者，差异有统计学意义(P＜0.01)；多因素分析结果表明：DD基因型、TT基因型、DD+TT组合基因型、治疗前醛固酮(Ald)水平是影响患者收缩压下降的主要因素。结论 ACE基因I／D多态性、α-adducin基因G614T多态性均与氢氯噻嗪的降压疗效相关；DD+TT组合基因型对HCTZ的降压反应可能优于其他组合基因型。
Objective To determine the correlation of antihypertensive effects of hydroehlorothiazide with polymorphism of ACE and α-adduein genes. Methods Antihypertensive response to HCTZ 12.5 mg once daily for 6 weeks were assessed in 829 patients with mild or moderate hypertension. ACE I/D and α-adduein G614T genotypes were determined in patients. Results Of 754 patients completed the study, the decrease in SBP of patients carrying DD of ACE gene was significantly greater than that in those with II or ID（ P〈0.05）. The decrease in SBP was significantly greater in patients with the TT genotype of α-adducin G614T as compared with GT or GG genotype[ P〈0.01）. Patients carrying 614T allele of α-adduein had the greatest DBP decrease after treatment （P〈0.01）. Multivariate stepwise regression analysis revealed that the DD genotype, TT genotype, the combination of the 2 genotypes, and the baseline aldosterone were the major determinants for the decreases in SBP. Conclusion The data suggests that the polymorphism of ACE I/D and α-adducin G614T might be associated with antihypertensive effect of HCTZ especially in the individuals with combination of DD＋TT genotypes.
出处
《高血压杂志》
CSCD
北大核心
2005年第11期697-700,共4页
Chinese Journal of Hypertension
